Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Methods: Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and...
Saved in:
Published in | International journal of gynecological cancer Vol. 23; no. 3; pp. 533 - 539 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.03.2013
Copyright by IGCS and ESGO Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 1048-891X 1525-1438 1525-1438 |
DOI | 10.1097/IGC.0b013e31828566f1 |
Cover
Abstract | We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Methods: Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m2) and vorinostat (400 mg) maintenance chemotherapy every 28 days.
Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure.
Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking. |
---|---|
AbstractList | We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.
Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days.
Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study's closure.
Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking. OBJECTIVESWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. METHODSPatients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board–approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days. RESULTSEighteen patients received a combined 90 cycles (median, 6 cycles; range, 1–6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1–12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure. CONCLUSIONSBecause the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking. ObjectivesWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.MethodsPatients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board–approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m2) and vorinostat (400 mg) maintenance chemotherapy every 28 days.ResultsEighteen patients received a combined 90 cycles (median, 6 cycles; range, 1–6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1–12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure.ConclusionsBecause the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking. We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma. Methods: Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m2), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m2) and vorinostat (400 mg) maintenance chemotherapy every 28 days. Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure. Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking. We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.OBJECTIVESWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days.METHODSPatients were treated with 6 cycles of weekly paclitaxel (80 mg/m), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board-approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m) and vorinostat (400 mg) maintenance chemotherapy every 28 days.Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study's closure.RESULTSEighteen patients received a combined 90 cycles (median, 6 cycles; range, 1-6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1-12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study's closure.Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking.CONCLUSIONSBecause the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel resection as part of their initial tumor debulking. |
Author | Abaid, Lisa N. Micha, John P. Brown, John V. Lopez, Katrina L. Goldstein, Bram H. Rettenmaier, Mark A. Mendivil, Alberto A. |
AuthorAffiliation | Gynecologic Oncology Associates, Newport Beach; and †The Women’s Cancer Research Foundation, Newport Beach, CA |
AuthorAffiliation_xml | – name: Gynecologic Oncology Associates, Newport Beach; and †The Women’s Cancer Research Foundation, Newport Beach, CA |
Author_xml | – sequence: 1 givenname: Alberto A. surname: Mendivil fullname: Mendivil, Alberto A. organization: Gynecologic Oncology Associates, Newport Beach – sequence: 2 givenname: John P. surname: Micha fullname: Micha, John P. organization: Gynecologic Oncology Associates, Newport Beach – sequence: 3 givenname: John V. surname: Brown fullname: Brown, John V. organization: Gynecologic Oncology Associates, Newport Beach – sequence: 4 givenname: Mark A. surname: Rettenmaier fullname: Rettenmaier, Mark A. organization: Gynecologic Oncology Associates, Newport Beach – sequence: 5 givenname: Lisa N. surname: Abaid fullname: Abaid, Lisa N. organization: Gynecologic Oncology Associates, Newport Beach – sequence: 6 givenname: Katrina L. surname: Lopez fullname: Lopez, Katrina L. organization: The Women’s Cancer Research Foundation, Newport Beach, CA – sequence: 7 givenname: Bram H. surname: Goldstein fullname: Goldstein, Bram H. email: bram@gynoncology.com organization: Gynecologic Oncology Associates, Newport Beach |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23385285$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkktvEzEUhUeoiD7gHyBkiQ2LTrHn4cywQKqiJlSK1Egtj93IY99pXBx7sD0J-ZX8JW6Z0kXEY2Uvznfu8T0-Tg6ss5AkLxk9Y7SevL2cT89oS1kOOauyquS8Y0-SI1ZmZcqKvDrAOy2qtKrZl8PkOIQ7Smmd0fpZcpjleVUic5T8uLTSgwigCN60AiuBuI5cwwY8kLkI0TttI4SorTDkYgM2BvJZxxWZaR9iutAWyFJIo6P4DuaUTIVvXW8EAqdEWEU-Oa-tC1FEMl3B2sUVeNHvSOc8OVcbgSNVeh3FLZCLHo3BaJx0tRFeC7RYer0WfkeW4HXEHQgz2s6EMa5HCbkZWsCx6OOfJ087YQK8eDhPko-zi5vph3RxNb-cni9SWVQlS3ndZkWbt6yus3LCiiLnPKtUxWsOAjjtFIdCqrLgHW05ACg5EYpxWgNXbVHnJ0k5-g62F7stRmn6MWfDaHNfUKNvZbNfEHJvRq737tuAW23WOkgwRlhwQ2hYzjI2yWlZovT1nvTODR5LCE1WYnt5yX6pXj2ohnYN6jHF74pR8G4USO9C8NA1EpuK2tnohTaPcfE__SlusQfvv_IvWDViW2ci-PDVDFvwzQq7i6v_oe9HFLC9jUYqSH3_K5X2IGOjnP63wU_6YvWS |
CitedBy_id | crossref_primary_10_2217_nnm_14_50 crossref_primary_10_1016_j_gore_2017_03_007 crossref_primary_10_3390_ijms23052496 crossref_primary_10_3389_fchem_2022_948217 crossref_primary_10_3389_fonc_2014_00111 crossref_primary_10_3389_fcell_2020_560117 crossref_primary_10_1158_0008_5472_CAN_19_3837 crossref_primary_10_1159_000510131 crossref_primary_10_1186_s40360_016_0075_8 crossref_primary_10_1016_j_jddst_2019_03_018 crossref_primary_10_3389_fonc_2024_1437953 crossref_primary_10_3390_cancers13081769 crossref_primary_10_1590_S1516_8913201500132 crossref_primary_10_1016_j_ygyno_2017_01_009 crossref_primary_10_1089_crsi_2017_0016 crossref_primary_10_3390_biom5043438 crossref_primary_10_3390_jcm13030897 crossref_primary_10_1016_j_critrevonc_2017_06_007 crossref_primary_10_1007_s00280_015_2813_9 crossref_primary_10_3390_ijms242015066 |
Cites_doi | 10.1007/s10147-011-0249-8 10.1200/JCO.2007.12.0782 10.1016/j.canlet.2009.01.002 10.7326/0003-4819-79-4-604 10.1186/1471-2407-6-183 10.1016/S0090-8258(03)00472-4 10.1006/gyno.1995.1140 10.1006/gyno.1997.4916 10.1002/cncr.21969 10.1111/j.0022-202X.2005.23925.x 10.1016/j.ygyno.2006.09.011 10.1097/IGC.0b013e3182070f17 10.1182/blood-2006-06-025999 10.1210/en.2006-0896 10.1158/1078-0432.CCR-03-0787 10.1016/j.ygyno.2009.09.039 10.1016/j.ygyno.2007.10.022 10.1200/JCO.1989.7.11.1748 10.1111/j.1447-0756.2010.01223.x 10.1016/j.ygyno.2008.01.009 10.1111/j.1525-1438.2007.00886.x 10.1016/S0090-8258(03)00128-8 10.1016/j.ygyno.2004.05.050 10.1016/j.ygyno.2007.06.004 10.1016/j.hoc.2011.10.004 10.1016/j.ejso.2008.01.005 10.1186/1755-8794-2-67 10.1158/1078-0432.CCR-05-2404 10.1002/jcp.22574 10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U 10.1093/jnci/92.3.205 10.1111/IGC.0b013e3181e94331 10.1200/JCO.2009.27.4696 10.1016/j.clbc.2011.04.002 |
ContentType | Journal Article |
Copyright | 2013 IGCS and ESGO Copyright © 2013 by IGCS and ESGO Copyright © 2013 by IGCS and ESGO2013 |
Copyright_xml | – notice: 2013 IGCS and ESGO – notice: Copyright © 2013 by IGCS and ESGO – notice: Copyright © 2013 by IGCS and ESGO2013 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 7X8 ADTOC UNPAY |
DOI | 10.1097/IGC.0b013e31828566f1 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest One Academic Eastern Edition MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1525-1438 |
EndPage | 539 |
ExternalDocumentID | 10.1097/igc.0b013e31828566f1 23385285 10_1097_IGC_0b013e31828566f1 10.1097/IGC.0b013e31828566f1 S1048891X24019042 |
Genre | Research Support, Non-U.S. Gov't Clinical Trial, Phase II Journal Article |
GroupedDBID | --- .3N .Z2 0R~ 1OC 29J 31~ 36B 4.4 53G 5GY 5VS 7X7 8-1 8FI 8FJ AAHLL AAKAS AARTV AAXUO ABBUW ABJNI ABUWG ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACWDW ACWRI ACXNZ ACXQS ADZCM AENEX AFBPY AFEBI AFKRA AFTRI AFZJQ AGINI AHEFC AIZYK AJAOE AJNYG AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS AWKKM BENPR BFHJK BQLVK CAG CCPQU CO8 COF CS3 CXRWF DC6 DCZOG E.X EBS EJD EX3 F5P FDB FL- FYUFA FZ0 HAJ HMCUK HZI HZ~ IHE IN~ KD2 L-C LH4 LW6 O9- OCUKA OHYEH ORVUJ OUVQU OVD OXXIT P2P RMJ ROL S4S TEORI UDS UKHRP V2I W3M W99 WOW X3V X3W YUY AAYWO M41 AALRI AAYXX ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP CITATION PHGZM CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PQEST PQQKQ PQUKI PRINS 7X8 ADTOC UNPAY |
ID | FETCH-LOGICAL-c4851-69b24b3b19925714436628d8696eae60fd6e4cd546f0b6eeedc7ad1609e6db493 |
IEDL.DBID | 7X7 |
ISSN | 1048-891X 1525-1438 |
IngestDate | Tue Aug 26 13:29:38 EDT 2025 Sat Sep 27 18:55:34 EDT 2025 Mon Jun 30 13:23:13 EDT 2025 Mon Jul 21 06:04:10 EDT 2025 Wed Oct 01 05:49:25 EDT 2025 Thu Apr 24 22:56:31 EDT 2025 Fri May 16 03:51:30 EDT 2025 Sat Dec 28 15:51:36 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Carboplatin Gynecologic oncology Chemotherapy Vorinostat Paclitaxel Ovarian cancer |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4851-69b24b3b19925714436628d8696eae60fd6e4cd546f0b6eeedc7ad1609e6db493 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://ijgc.bmj.com/content/ijgc/23/3/533.full.pdf |
PMID | 23385285 |
PQID | 2552835155 |
PQPubID | 5161120 |
PageCount | 7 |
ParticipantIDs | unpaywall_primary_10_1097_igc_0b013e31828566f1 proquest_miscellaneous_1312173055 proquest_journals_2552835155 pubmed_primary_23385285 crossref_citationtrail_10_1097_IGC_0b013e31828566f1 crossref_primary_10_1097_IGC_0b013e31828566f1 wolterskluwer_health_10_1097_IGC_0b013e31828566f1 elsevier_sciencedirect_doi_10_1097_IGC_0b013e31828566f1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March 2013 2013-March 2013-03-00 2013-Mar 20130301 |
PublicationDateYYYYMMDD | 2013-03-01 |
PublicationDate_xml | – month: 03 year: 2013 text: March 2013 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Kidlington |
PublicationTitle | International journal of gynecological cancer |
PublicationTitleAlternate | Int J Gynecol Cancer |
PublicationYear | 2013 |
Publisher | Elsevier Inc Copyright by IGCS and ESGO Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Copyright by IGCS and ESGO – name: Elsevier Limited |
References | Chobanian, Greenberg, Gass (bb0020) 2004; 24 Rustin, Marples, Nelstrop (bb0090) 2004; 10 Rose, Piver (bb0140) 1995; 57 Duvic, Talpur, Ni (bb0040) 2007; 109 Yardley, Raefsky, Castillo (bb0155) 2011; 11 Schorge, Eisenhauer, Chi (bb0130) 2012; 26 Eisenhauer, Abu-Rustum, Sonoda (bb0055) 2008; 108 (bb0080) 2010 Calvert, Newell, Gunbrell (bb0070) 1989; 7 Colombo, Mourregot, Fabbro (bb0125) 2009; 35 Zhang, Richon, Ni (bb0035) 2005; 125 Cannistra, Matulonis, Penson (bb0185) 2007; 25 Modesitt (bb0045) 2008; 109 Wright, Hagemann, Rader (bb0190) 2006; 107 Micha, Goldstein, Rettenmaier (bb0015) 2004; 94 Kim, Kim, Wu (bb0145) 2010; 36 Sonnemann, Gänge, Pilz (bb0030) 2006; 6 Erjala, Sundvall, Junttila (bb0175) 2006; 12 de Haan, van den Berg (bb0150) 2006; 29 Simpkins, Belinson, Rose (bb0195) 2007; 107 Siegel, Naishadham, Jemal (bb0005) 2012; 62 Romanini, Tanganelli, Carnino (bb0115) 2003; 89 Uchida, Maruyama, Ono (bb0180) 2007; 148 Muraoka, Tsukuda, Toyooka (bb0165) 2011; 16 Micha, Goldstein, Rettenmaier (bb0120) 2007; 17 Richon, Garcia-Vargas, Hardwick (bb0105) 2009; 280 Brown, Micha, Rettenmaier (bb0135) 2010; 20 Stuart (bb0110) 2003; 90 du Bois, Herrstedt, Hardy-Bessard (bb0010) 2010; 28 Therasse, Arbuck (bb0085) 2000; 92 . Brown, Rettenmaier, Dillman (bb0060) 1998; 68 Rustin, Vergote, Eisenhauer (bb0095) 2011; 21 Jelliffe (bb0075) 1973; 79 Dietrich, Greenberg, DeSimone (bb0025) 2010; 116 Cooper, Greenberg, Lancaster (bb0050) 2007; 104 Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. 2007;4:337-343. Hainsworth, Greco (bb0065) 1994; 74 LaBonte, Wilson, Fazzone (bb0160) 2009; 2 Bruzzese, Leone, Rocco (bb0170) 2011; 226 Calvert (10.1097/IGC.0b013e31828566f1_bb0070) 1989; 7 Bruzzese (10.1097/IGC.0b013e31828566f1_bb0170) 2011; 226 Micha (10.1097/IGC.0b013e31828566f1_bb0120) 2007; 17 Simpkins (10.1097/IGC.0b013e31828566f1_bb0195) 2007; 107 Cooper (10.1097/IGC.0b013e31828566f1_bb0050) 2007; 104 Richon (10.1097/IGC.0b013e31828566f1_bb0105) 2009; 280 Erjala (10.1097/IGC.0b013e31828566f1_bb0175) 2006; 12 Colombo (10.1097/IGC.0b013e31828566f1_bb0125) 2009; 35 Micha (10.1097/IGC.0b013e31828566f1_bb0015) 2004; 94 Cannistra (10.1097/IGC.0b013e31828566f1_bb0185) 2007; 25 Brown (10.1097/IGC.0b013e31828566f1_bb0135) 2010; 20 Dietrich (10.1097/IGC.0b013e31828566f1_bb0025) 2010; 116 Eisenhauer (10.1097/IGC.0b013e31828566f1_bb0055) 2008; 108 du Bois (10.1097/IGC.0b013e31828566f1_bb0010) 2010; 28 10.1097/IGC.0b013e31828566f1_or0005 Stuart (10.1097/IGC.0b013e31828566f1_bb0110) 2003; 90 Chobanian (10.1097/IGC.0b013e31828566f1_bb0020) 2004; 24 Kim (10.1097/IGC.0b013e31828566f1_bb0145) 2010; 36 Zhang (10.1097/IGC.0b013e31828566f1_bb0035) 2005; 125 Romanini (10.1097/IGC.0b013e31828566f1_bb0115) 2003; 89 Rustin (10.1097/IGC.0b013e31828566f1_bb0095) 2011; 21 Jelliffe (10.1097/IGC.0b013e31828566f1_bb0075) 1973; 79 Rustin (10.1097/IGC.0b013e31828566f1_bb0090) 2004; 10 Siegel (10.1097/IGC.0b013e31828566f1_bb0005) 2012; 62 (10.1097/IGC.0b013e31828566f1_bb0080) 2010 Duvic (10.1097/IGC.0b013e31828566f1_bb0040) 2007; 109 Therasse (10.1097/IGC.0b013e31828566f1_bb0085) 2000; 92 Uchida (10.1097/IGC.0b013e31828566f1_bb0180) 2007; 148 Schorge (10.1097/IGC.0b013e31828566f1_bb0130) 2012; 26 LaBonte (10.1097/IGC.0b013e31828566f1_bb0160) 2009; 2 Muraoka (10.1097/IGC.0b013e31828566f1_bb0165) 2011; 16 Rose (10.1097/IGC.0b013e31828566f1_bb0140) 1995; 57 Hainsworth (10.1097/IGC.0b013e31828566f1_bb0065) 1994; 74 de Haan (10.1097/IGC.0b013e31828566f1_bb0150) 2006; 29 Yardley (10.1097/IGC.0b013e31828566f1_bb0155) 2011; 11 10.1097/IGC.0b013e31828566f1_or0010 Wright (10.1097/IGC.0b013e31828566f1_bb0190) 2006; 107 Modesitt (10.1097/IGC.0b013e31828566f1_bb0045) 2008; 109 Sonnemann (10.1097/IGC.0b013e31828566f1_bb0030) 2006; 6 Brown (10.1097/IGC.0b013e31828566f1_bb0060) 1998; 68 |
References_xml | – volume: 25 start-page: 5180 year: 2007 end-page: 5186 ident: bb0185 article-title: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer publication-title: J Clin Oncol. – volume: 24 start-page: 539 year: 2004 end-page: 545 ident: bb0020 article-title: Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status publication-title: . – volume: 226 start-page: 2378 year: 2011 end-page: 2390 ident: bb0170 article-title: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT publication-title: . – volume: 109 start-page: 182 year: 2008 end-page: 186 ident: bb0045 article-title: Sill M, Hoffman JS, et al; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study publication-title: . – volume: 57 start-page: 270 year: 1995 end-page: 272 ident: bb0140 article-title: Intestinal perforation secondary to paclitaxel publication-title: . – volume: 109 start-page: 31 year: 2007 end-page: 39 ident: bb0040 article-title: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) publication-title: . – volume: 6 start-page: 183 year: 2006 ident: bb0030 article-title: Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients publication-title: . – volume: 7 start-page: 1748 year: 1989 end-page: 1756 ident: bb0070 article-title: Carboplatin dosage: prospective evaluation of a simple formula based on renal function publication-title: . – volume: 79 start-page: 605 year: 1973 ident: bb0075 article-title: Creatinine clearance: bedside estimate publication-title: . – volume: 20 start-page: 1132 year: 2010 end-page: 1136 ident: bb0135 article-title: A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma publication-title: . – volume: 62 start-page: 10 year: 2012 end-page: 29 ident: bb0005 article-title: Cancer statistics, 2012 publication-title: . – volume: 280 start-page: 201 year: 2009 end-page: 210 ident: bb0105 article-title: Development of vorinostat: current applications and future perspectives for cancer therapy publication-title: . – volume: 108 start-page: 276 year: 2008 end-page: 281 ident: bb0055 article-title: The effect of maximal surgical cytoreduction on sensitivity to platinum- taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer publication-title: . – volume: 26 start-page: 93 year: 2012 end-page: 109 ident: bb0130 article-title: Current surgical management of ovarian cancer publication-title: . – volume: 148 start-page: 896 year: 2007 end-page: 902 ident: bb0180 article-title: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin publication-title: Endocrinology. – volume: 36 start-page: 598 year: 2010 end-page: 604 ident: bb0145 article-title: Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience publication-title: . – volume: 94 start-page: 719 year: 2004 end-page: 724 ident: bb0015 article-title: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer publication-title: . – volume: 74 start-page: 1 year: 1994 ident: bb0065 article-title: Paclitaxel administered by 1-hour infusion publication-title: . – volume: 12 start-page: 4103 year: 2006 end-page: 4111 ident: bb0175 article-title: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells publication-title: Clin Cancer Res. – year: 2010 ident: bb0080 publication-title: National Cancer Institute: Common Terminology Criteria for Adverse Events (version 4.03) – volume: 90 start-page: S8 year: 2003 end-page: S15 ident: bb0110 article-title: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer publication-title: . – volume: 92 start-page: 205 year: 2000 end-page: 216 ident: bb0085 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: . – volume: 11 start-page: 297 year: 2011 end-page: 305 ident: bb0155 article-title: Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer publication-title: . – volume: 107 start-page: 118 year: 2007 end-page: 123 ident: bb0195 article-title: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening publication-title: . – reference: Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. – volume: 68 start-page: 166 year: 1998 end-page: 168 ident: bb0060 article-title: Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer publication-title: . – volume: 21 start-page: 419 year: 2011 end-page: 423 ident: bb0095 article-title: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) publication-title: . – volume: 2 start-page: 67 year: 2009 ident: bb0160 article-title: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines publication-title: . – volume: 35 start-page: 135 year: 2009 end-page: 143 ident: bb0125 article-title: Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients publication-title: . – volume: 10 start-page: 3919 year: 2004 end-page: 3926 ident: bb0090 article-title: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer publication-title: . – reference: . – reference: 2007;4:337-343. – volume: 17 start-page: 771 year: 2007 end-page: 776 ident: bb0120 article-title: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer publication-title: . – volume: 29 start-page: 541 year: 2006 end-page: 542 ident: bb0150 article-title: Colonic perforation secondary to taxol therapy: an unusual presentation publication-title: . – volume: 125 start-page: 1045 year: 2005 end-page: 1052 ident: bb0035 article-title: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action publication-title: . – volume: 16 start-page: 774 year: 2011 end-page: 777 ident: bb0165 article-title: Ileal perforation induced by acute radiation injury under gefitinib treatment publication-title: Int J Clin Oncol. – volume: 28 start-page: 4162 year: 2010 end-page: 4169 ident: bb0010 article-title: Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer publication-title: . – volume: 104 start-page: 596 year: 2007 end-page: 601 ident: bb0050 article-title: In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer publication-title: . – volume: 107 start-page: 83 year: 2006 end-page: 89 ident: bb0190 article-title: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis publication-title: . – volume: 116 start-page: 126 year: 2010 end-page: 130 ident: bb0025 article-title: Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines publication-title: . – volume: 89 start-page: 354 year: 2003 end-page: 359 ident: bb0115 article-title: First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients publication-title: . – volume: 16 start-page: 774 year: 2011 ident: 10.1097/IGC.0b013e31828566f1_bb0165 article-title: Ileal perforation induced by acute radiation injury under gefitinib treatment publication-title: Int J Clin Oncol. doi: 10.1007/s10147-011-0249-8 – volume: 25 start-page: 5180 year: 2007 ident: 10.1097/IGC.0b013e31828566f1_bb0185 article-title: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer publication-title: J Clin Oncol. doi: 10.1200/JCO.2007.12.0782 – volume: 280 start-page: 201 year: 2009 ident: 10.1097/IGC.0b013e31828566f1_bb0105 article-title: Development of vorinostat: current applications and future perspectives for cancer therapy publication-title: Cancer Lett. doi: 10.1016/j.canlet.2009.01.002 – volume: 79 start-page: 605 year: 1973 ident: 10.1097/IGC.0b013e31828566f1_bb0075 article-title: Creatinine clearance: bedside estimate publication-title: Ann Intern Med. doi: 10.7326/0003-4819-79-4-604 – volume: 29 start-page: 541 year: 2006 ident: 10.1097/IGC.0b013e31828566f1_bb0150 article-title: Colonic perforation secondary to taxol therapy: an unusual presentation publication-title: Onkologie. – volume: 6 start-page: 183 year: 2006 ident: 10.1097/IGC.0b013e31828566f1_bb0030 article-title: Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients publication-title: BMC Cancer. doi: 10.1186/1471-2407-6-183 – ident: 10.1097/IGC.0b013e31828566f1_or0005 – volume: 90 start-page: S8 year: 2003 ident: 10.1097/IGC.0b013e31828566f1_bb0110 article-title: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer publication-title: Gynecol Oncol. doi: 10.1016/S0090-8258(03)00472-4 – volume: 57 start-page: 270 year: 1995 ident: 10.1097/IGC.0b013e31828566f1_bb0140 article-title: Intestinal perforation secondary to paclitaxel publication-title: Gynecol Oncol. doi: 10.1006/gyno.1995.1140 – volume: 68 start-page: 166 year: 1998 ident: 10.1097/IGC.0b013e31828566f1_bb0060 article-title: Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer publication-title: Gynecol Oncol. doi: 10.1006/gyno.1997.4916 – volume: 24 start-page: 539 year: 2004 ident: 10.1097/IGC.0b013e31828566f1_bb0020 article-title: Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status publication-title: Anticancer Res. – volume: 107 start-page: 83 year: 2006 ident: 10.1097/IGC.0b013e31828566f1_bb0190 article-title: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis publication-title: Cancer. doi: 10.1002/cncr.21969 – volume: 125 start-page: 1045 year: 2005 ident: 10.1097/IGC.0b013e31828566f1_bb0035 article-title: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action publication-title: J Invest Dermatol. doi: 10.1111/j.0022-202X.2005.23925.x – volume: 104 start-page: 596 year: 2007 ident: 10.1097/IGC.0b013e31828566f1_bb0050 article-title: In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2006.09.011 – year: 2010 ident: 10.1097/IGC.0b013e31828566f1_bb0080 – volume: 21 start-page: 419 year: 2011 ident: 10.1097/IGC.0b013e31828566f1_bb0095 article-title: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) publication-title: Int J Gynecol Cancer. doi: 10.1097/IGC.0b013e3182070f17 – volume: 62 start-page: 10 year: 2012 ident: 10.1097/IGC.0b013e31828566f1_bb0005 article-title: Cancer statistics, 2012 publication-title: CA Cancer J Clin. – volume: 109 start-page: 31 year: 2007 ident: 10.1097/IGC.0b013e31828566f1_bb0040 article-title: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) publication-title: Blood. doi: 10.1182/blood-2006-06-025999 – volume: 148 start-page: 896 year: 2007 ident: 10.1097/IGC.0b013e31828566f1_bb0180 article-title: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin publication-title: Endocrinology. doi: 10.1210/en.2006-0896 – volume: 10 start-page: 3919 year: 2004 ident: 10.1097/IGC.0b013e31828566f1_bb0090 article-title: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-03-0787 – volume: 116 start-page: 126 year: 2010 ident: 10.1097/IGC.0b013e31828566f1_bb0025 article-title: Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2009.09.039 – volume: 108 start-page: 276 year: 2008 ident: 10.1097/IGC.0b013e31828566f1_bb0055 article-title: The effect of maximal surgical cytoreduction on sensitivity to platinum- taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2007.10.022 – volume: 7 start-page: 1748 year: 1989 ident: 10.1097/IGC.0b013e31828566f1_bb0070 article-title: Carboplatin dosage: prospective evaluation of a simple formula based on renal function publication-title: J Clin Oncol. doi: 10.1200/JCO.1989.7.11.1748 – volume: 36 start-page: 598 year: 2010 ident: 10.1097/IGC.0b013e31828566f1_bb0145 article-title: Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience publication-title: J Obstet Gynaecol Res. doi: 10.1111/j.1447-0756.2010.01223.x – volume: 109 start-page: 182 year: 2008 ident: 10.1097/IGC.0b013e31828566f1_bb0045 article-title: Sill M, Hoffman JS, et al; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2008.01.009 – ident: 10.1097/IGC.0b013e31828566f1_or0010 – volume: 17 start-page: 771 year: 2007 ident: 10.1097/IGC.0b013e31828566f1_bb0120 article-title: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer publication-title: Int J Gynecol Cancer. doi: 10.1111/j.1525-1438.2007.00886.x – volume: 89 start-page: 354 year: 2003 ident: 10.1097/IGC.0b013e31828566f1_bb0115 article-title: First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients publication-title: Gynecol Oncol. doi: 10.1016/S0090-8258(03)00128-8 – volume: 94 start-page: 719 year: 2004 ident: 10.1097/IGC.0b013e31828566f1_bb0015 article-title: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2004.05.050 – volume: 107 start-page: 118 year: 2007 ident: 10.1097/IGC.0b013e31828566f1_bb0195 article-title: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2007.06.004 – volume: 26 start-page: 93 year: 2012 ident: 10.1097/IGC.0b013e31828566f1_bb0130 article-title: Current surgical management of ovarian cancer publication-title: Hematol Oncol Clin North Am. doi: 10.1016/j.hoc.2011.10.004 – volume: 35 start-page: 135 year: 2009 ident: 10.1097/IGC.0b013e31828566f1_bb0125 article-title: Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients publication-title: Eur J Surg Oncol. doi: 10.1016/j.ejso.2008.01.005 – volume: 2 start-page: 67 year: 2009 ident: 10.1097/IGC.0b013e31828566f1_bb0160 article-title: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines publication-title: BMC Med Genomics. doi: 10.1186/1755-8794-2-67 – volume: 12 start-page: 4103 year: 2006 ident: 10.1097/IGC.0b013e31828566f1_bb0175 article-title: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-05-2404 – volume: 226 start-page: 2378 year: 2011 ident: 10.1097/IGC.0b013e31828566f1_bb0170 article-title: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT publication-title: J Cell Physiol. doi: 10.1002/jcp.22574 – volume: 74 start-page: 1 year: 1994 ident: 10.1097/IGC.0b013e31828566f1_bb0065 article-title: Paclitaxel administered by 1-hour infusion publication-title: Cancer. doi: 10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U – volume: 92 start-page: 205 year: 2000 ident: 10.1097/IGC.0b013e31828566f1_bb0085 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/92.3.205 – volume: 20 start-page: 1132 year: 2010 ident: 10.1097/IGC.0b013e31828566f1_bb0135 article-title: A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma publication-title: Int J Gynecol Cancer. doi: 10.1111/IGC.0b013e3181e94331 – volume: 28 start-page: 4162 year: 2010 ident: 10.1097/IGC.0b013e31828566f1_bb0010 article-title: Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer publication-title: J Clin Oncol. doi: 10.1200/JCO.2009.27.4696 – volume: 11 start-page: 297 year: 2011 ident: 10.1097/IGC.0b013e31828566f1_bb0155 article-title: Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer publication-title: Clin Breast Cancer. doi: 10.1016/j.clbc.2011.04.002 |
SSID | ssj0009209 |
Score | 2.1306243 |
Snippet | We sought to assess the response rate and toxicity of paclitaxel, carboplatin, and vorinostat primary induction therapy for the treatment of advanced-stage... OBJECTIVESWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of... We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage... ObjectivesWe sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of... |
SourceID | unpaywall proquest pubmed crossref wolterskluwer elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 533 |
SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Carboplatin Carboplatin - administration & dosage Chemotherapy Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - mortality Cystadenocarcinoma, Serous - pathology Endometrial Neoplasms - drug therapy Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - mortality Fallopian Tube Neoplasms - pathology Female Follow-Up Studies Gastrointestinal Diseases - chemically induced Gastrointestinal Diseases - epidemiology Genital cancers Gynecologic oncology Gynecological cancer Humans Hydroxamic Acids - administration & dosage Incidence Middle Aged Neoadjuvant Therapy Neoplasm Grading Neoplasm Staging Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Ovaries Paclitaxel Paclitaxel - administration & dosage Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - mortality Peritoneal Neoplasms - pathology Prognosis Prospective Studies Response rates Survival Rate Vorinostat |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELagk0AT4nWMooGMxMc5TeLUST5WVbuBtFGJFsqnyHbc0S1LojZljD_JX-KuTirYgGnforycc9Kd_Zzv7jEhb1XMPeHriKWxiVkQuJpFXCvma60jHslYBdg7fHQsDifB-2l3Wvdxr3thTk-0o85PbTsDEjTl1fpmx-cd3gFw4uC-tFOms7tkS2BWqUW2Jsej3hfLOxCxKPama5ZUv8vwcO-mYS4OO3MQvtn58yOAMjPvXwvSdcC5Te6v8lJeXsgs2yYPLgrMZy_P1uXsvy1Kw0dk3Khja1HOnFWlHP3jCtPjLfV9TB7WIJX2rFU9IXdM_pTcO6rT8M_IT5hVsJjdpBSu7LGktJjRjwYcw9ADuawWBRJRwPyBggZYVLmkn-fVVzqcA95kEAIbOpIaKcK_m2yf9uVCFSUW5uX7VOYp_YSVgQX2O1EkNagbxS4pgGzaqwsXGEDlE0MHJTaWZOBJ9MM3iP0liBhZFg06Ag9DvnGZWbFDLDQo4RU6XikDw4KcxQ6ZDAfj_iGrT4ZgOgCIyESs_EBxhbWz3RBiQi6EH6WRiIWRRrizVJhAp91AzFwlDOAAHcrUE25sRKqCmD8nrRzGfkGoJwCDpQiDPAkPAhW6vlYul26oedSVbcIb80h0TZuOp3dkSZO-f3fQT64aVZuwzVelVfiG98PG8pIa-lhIk8DKdsOXe42hJvX0s0wgTkQePcCKbfJm8xgmDswGydwUq2XicQ_CUSR8a5Nda-CbX_U5qA4DtImzsfhreoAz_eVvvD_cIrHdvP_V4OVtB9kjrWqxMq8ADVbqde39vwCmvlve priority: 102 providerName: Unpaywall |
Title | Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
URI | https://dx.doi.org/10.1097/IGC.0b013e31828566f1 https://www.ncbi.nlm.nih.gov/pubmed/23385285 https://www.proquest.com/docview/2552835155 https://www.proquest.com/docview/1312173055 https://ijgc.bmj.com/content/ijgc/23/3/533.full.pdf |
UnpaywallVersion | publishedVersion |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1525-1438 dateEnd: 20141231 omitProxy: true ssIdentifier: ssj0009209 issn: 1525-1438 databaseCode: 7X7 dateStart: 20130101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central Database Suite (ProQuest) customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1525-1438 dateEnd: 20141231 omitProxy: true ssIdentifier: ssj0009209 issn: 1525-1438 databaseCode: BENPR dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZgk4AJIX6OwJiMxOPMkjh1kidUqnYDaSWCFbqnyHbcUS1KQtMy9lfyL3HXOC0w2J4SKYmdk8_2d77v7gh5pWLuCV9HLItNzILA1SziWjFfax3xSMYqwNjho6E4HAXvx52xPXCrLa2yXROXC3VWajwj3wfoi6nBYPt7U31jWDUKvau2hMZNsukBVEGtDsfhOuluQ_EAiyNiUeyN29C5ONx_d9BbnwH6EYCaife_reky9NwitxdFJS_OZZ5vkbvnJXq267Mlsf237Wlwn9yzuJJ2G0V4QG6Y4iG5dWQ954_IT1gIkH9uMgp3TSVRWk7oJwO6bOiBrOezEnNHwJTHhvrIg6zpl-n8Kx1MASIysFoNTaTGrN4_TL5He3Kmygq5dMUelUVGPyOZr8QQJYp5CGxs1wUFXEy7lmvAAN2eGtqvMBYkB-WnH76DuS6hiaRJfEETmBSYIlzmTbMD5AZU8Ao9XigD3UI7s8dkNOgf9w6ZLebAdACojolY-YHiCumunRDMOC6EH2WRiIWRRriTTJhAZ51ATFwlDGzdOpSZJ9zYiEwFMX9CNgro-ymhngDYlCFy8SQ8CFTo-lq5XLqh5lFHOoS345hqm-kcC27kaetxh9FP_x59h7DVV1Uj8DXvh62KpBatNCgkhc3omi93Wo1K7YpRp2v9dsjL1WOY6-jAkYUpF3XqcQ8sSMzR5pDtRhNXv-pzEB06cMjrlWpekmN6qv_xN94f-ps2AbhXSvDsagmekzv-smoIUvV2yMZ8tjAvALvN1e5ygu6Szbf9YfIRrqNh0j35BbnvQhI |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLWmITEmhPgmMMBI8DazfLhO8oDQVNq1bB2V6KBvwXbcUREloWkp_VP8Ff4S9zZJCwy2p71FSmLH8r3Xx_G55xLyXIWeI1wdsDg0IePc1izwtGKu1jrwAhkqjrnDvWPROeFvh43hBvlR58IgrbKOictAHWca_5HvAfRFaTBY_l7nXxlWjcLT1bqERmkWh2Yxhy1b8ar7Bub3heu2W4Nmh1VVBZjmAC-YCJXLlaeQd9nwYT_hCeEGcSBCYaQR9igWhuu4wcXIVsLAGqJ9GTvCDo2IFUfxJQj5V7hnc9Tq94f-WuS3pJTADidgQegM61S90N_rHjTX_xzdAEDUyPnfUngW6m6TrVmay8VcJsk2uT7P8CS9-LIk0v-2HLZvkhsVjqX7peHdIhsmvU2u9qqT-jvkJwQe5LubmMJVWbmUZiP63oDvGHogi-kkQ60KCDHYUAt5lwX9OJ5-pu0xQFIGu2RD-1Kjivh3k-zSppyoLEfuXrpLZRrTD0gezDAliqLuQZVLtqCAw-l-xW1ggKZPDW3lmHuSgLPRd98kOB000S-FNmgfnBAlyWVSNttGLkIOj9DBTBnoFtqZ3CUnlzLN98hmCn0_INQRANNiREqOhBtc-barle1J29de0JAW8ep5jHSlrI4FPpKoPuGH2Y_-nn2LsNVbeTngC573axOJKnRUop4IFr8L3typLSqqIlQRrf3JIs9WtyG24IGRTE02KyLHc2DHippwFrlfWuLqU10Phg4dWOTlyjTPjGN8qv_xNc4f9huVCb_njuDh-SN4SrY6g95RdNQ9PnxErrnLiiVIE9whm9PJzDwG3DhVT5bOSsmny44OvwCkVHsk |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLamIQ0mhPinMMBIcDfTJHad5AKhqWu3MjYqsUHvgu24oyJKQtNS-mq8BK_EOU3SAoPtaneRktixzt_n-DvnEPJch9yVnglYHNqQCeEYFnCjmWeMCXigQi0wd_jwSO6fiDeD1mCN_KhzYZBWWfvEhaOOM4P_yJsAfbE0GIS_5rCiRfR3u6_zrww7SOFJa91Oo1SRAzufwfateNXbBVm_8Lxu57i9z6oOA8wIgBpMhtoTmmvkYLZ82FtwKb0gDmQorbLSGcbSChO3hBw6WlqIJ8ZXsSud0MpYCyzEBO7_is8FRzqZP_BXBX9LegnsdgIWhO6gTtsL_WZvr736_-gFAKiG7v_C4lnYu0muTtNczWcqSTbJ9VmGp-rFlwWp_rfQ2L1JblSYlu6USniLrNn0Ntk4rE7t75Cf4ISQ-25jCldlF1OaDel7C3Zk6Z4qJuMM61aAu8GBOsjBLOjH0eQz7Y4AnjLYMVvaVwYrin-3yTZtq7HOcuTxpdtUpTH9gETCDNOjKNZAqPLK5hQwOd2peA4MkPWppZ0c81ASMDz67psCA4Qh-mXRDdoHg8Ty5Coph-0iLyGHR-jxVFuYFsYZ3yUnlyLme2Q9hbkfEOpKgGwxoiZXwQ2hfccz2uHK8Q0PWqpBeC3HyFRV1rHZRxLVp_0g_ehv6TcIW76Vlwu-4Hm_VpGoQkolAoogEF7w5latUVHlrYpoZVsN8mx5G_wMHh6p1GbTInK5C7tXrA_XIPdLTVx-qsdh6TBBg7xcquaZdYxOzT--xv1Df6My-ffcFTw8fwVPyQb4heht7-jgEbnmLZqXIGNwi6xPxlP7GCDkRD9Z2Colny7bOfwCwIZ_Xw |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELagk0AT4nWMooGMxMc5TeLUST5WVbuBtFGJFsqnyHbc0S1LojZljD_JX-KuTirYgGnforycc9Kd_Zzv7jEhb1XMPeHriKWxiVkQuJpFXCvma60jHslYBdg7fHQsDifB-2l3Wvdxr3thTk-0o85PbTsDEjTl1fpmx-cd3gFw4uC-tFOms7tkS2BWqUW2Jsej3hfLOxCxKPama5ZUv8vwcO-mYS4OO3MQvtn58yOAMjPvXwvSdcC5Te6v8lJeXsgs2yYPLgrMZy_P1uXsvy1Kw0dk3Khja1HOnFWlHP3jCtPjLfV9TB7WIJX2rFU9IXdM_pTcO6rT8M_IT5hVsJjdpBSu7LGktJjRjwYcw9ADuawWBRJRwPyBggZYVLmkn-fVVzqcA95kEAIbOpIaKcK_m2yf9uVCFSUW5uX7VOYp_YSVgQX2O1EkNagbxS4pgGzaqwsXGEDlE0MHJTaWZOBJ9MM3iP0liBhZFg06Ag9DvnGZWbFDLDQo4RU6XikDw4KcxQ6ZDAfj_iGrT4ZgOgCIyESs_EBxhbWz3RBiQi6EH6WRiIWRRrizVJhAp91AzFwlDOAAHcrUE25sRKqCmD8nrRzGfkGoJwCDpQiDPAkPAhW6vlYul26oedSVbcIb80h0TZuOp3dkSZO-f3fQT64aVZuwzVelVfiG98PG8pIa-lhIk8DKdsOXe42hJvX0s0wgTkQePcCKbfJm8xgmDswGydwUq2XicQ_CUSR8a5Nda-CbX_U5qA4DtImzsfhreoAz_eVvvD_cIrHdvP_V4OVtB9kjrWqxMq8ADVbqde39vwCmvlve |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+Incidence+of+Severe+Gastrointestinal+Events+With+First-Line+Paclitaxel%2C+Carboplatin%2C+and+Vorinostat+Chemotherapy+for+Advanced-Stage+Epithelial+Ovarian%2C+Primary+Peritoneal%2C+and+Fallopian+Tube+Cancer&rft.jtitle=International+journal+of+gynecological+cancer&rft.au=Mendivil%2C+Alberto+A.&rft.au=Micha%2C+John+P.&rft.au=Brown%2C+John+V.&rft.au=Rettenmaier%2C+Mark+A.&rft.date=2013-03-01&rft.pub=Elsevier+Inc&rft.issn=1048-891X&rft.volume=23&rft.issue=3&rft.spage=533&rft.epage=539&rft_id=info:doi/10.1097%2FIGC.0b013e31828566f1&rft.externalDocID=S1048891X24019042 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1048-891X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1048-891X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1048-891X&client=summon |